Katsuhiko Naoki

16.8k total citations · 1 hit paper
125 papers, 11.6k citations indexed

About

Katsuhiko Naoki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Katsuhiko Naoki has authored 125 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pulmonary and Respiratory Medicine, 74 papers in Oncology and 47 papers in Molecular Biology. Recurrent topics in Katsuhiko Naoki's work include Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (39 papers) and Colorectal Cancer Treatments and Studies (19 papers). Katsuhiko Naoki is often cited by papers focused on Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (39 papers) and Colorectal Cancer Treatments and Studies (19 papers). Katsuhiko Naoki collaborates with scholars based in Japan, United States and France. Katsuhiko Naoki's co-authors include Matthew Meyerson, Pasi A. Jänne, Jeffrey C. Lee, William R. Sellers, Bruce E. Johnson, Michael J. Eck, Sean Tracy, J. Guillermo Paez, Neal I. Lindeman and Titus J. Boggon and has published in prestigious journals such as Science, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Katsuhiko Naoki

123 papers receiving 11.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. Science profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Katsuhiko Naoki	7.5k	6.2k	5.0k	2.7k	811	125	11.6k
Ross A. Okimoto	8.1k 1.1×	7.3k 1.2×	4.9k 1.0×	2.7k 1.0×	868 1.1×	33	12.1k
Hidefumi Sasaki	7.3k 1.0×	6.4k 1.0×	5.0k 1.0×	2.7k 1.0×	714 0.9×	143	11.9k
Balázs Halmos	7.6k 1.0×	8.0k 1.3×	4.9k 1.0×	2.2k 0.8×	906 1.1×	280	12.7k
Tim Eisen	7.0k 0.9×	4.4k 0.7×	7.4k 1.5×	4.1k 1.5×	854 1.1×	145	12.8k
Isamu Okamoto	9.4k 1.3×	9.5k 1.5×	4.1k 0.8×	2.0k 0.7×	836 1.0×	383	13.9k
Tarek Mekhail	6.9k 0.9×	5.8k 0.9×	3.0k 0.6×	1.8k 0.7×	594 0.7×	170	10.6k
Katerina Politi	7.4k 1.0×	7.2k 1.1×	5.5k 1.1×	2.8k 1.0×	758 0.9×	113	12.0k
Toyoaki Hida	8.5k 1.1×	8.1k 1.3×	4.0k 0.8×	2.0k 0.7×	583 0.7×	280	13.4k
Seiji Yano	4.9k 0.7×	5.2k 0.8×	4.3k 0.9×	1.6k 0.6×	629 0.8×	253	9.6k
Jin‐Yuan Shih	6.9k 0.9×	6.4k 1.0×	4.0k 0.8×	2.3k 0.9×	675 0.8×	259	10.7k

Countries citing papers authored by Katsuhiko Naoki

Since Specialization

Citations

This map shows the geographic impact of Katsuhiko Naoki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katsuhiko Naoki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katsuhiko Naoki more than expected).

Fields of papers citing papers by Katsuhiko Naoki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katsuhiko Naoki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katsuhiko Naoki. The network helps show where Katsuhiko Naoki may publish in the future.

Co-authorship network of co-authors of Katsuhiko Naoki

This figure shows the co-authorship network connecting the top 25 collaborators of Katsuhiko Naoki. A scholar is included among the top collaborators of Katsuhiko Naoki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katsuhiko Naoki. Katsuhiko Naoki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamamoto, Hiroki, Masayuki Shirasawa, & Katsuhiko Naoki. (2025). Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975–2022 with insights on the impact of COVID-19. International Journal of Clinical Oncology. 30(2). 199–209. 2 indexed citations

Niho, Seiji, Masahiro Tsuboi, Masashi Wakabayashi, et al.. (2024). 1788P Final overall survival analysis of JCOG1205/1206: Phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung. Annals of Oncology. 35. S1063–S1063. 1 indexed citations

Horinouchi, Hidehito, Shogo Nomura, Satoshi Igawa, et al.. (2023). Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy. Journal of Thoracic Oncology. 19(2). 325–336. 9 indexed citations

Shimokawa, Tsuneo, Yuichi Takiguchi, Toshihiro Misumi, et al.. (2022). A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630. Clinical Cancer Research. 28(20). 4402–4409. 19 indexed citations

Igawa, Satoshi, Masanori Yokoba, Akira Takakura, et al.. (2021). Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease. Investigational New Drugs. 40(1). 182–189. 2 indexed citations

Yasuda, Hiroyuki, Keigo Kobayashi, Tetsuo Tani, et al.. (2019). Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics. 18(9). 1593–1601. 3 indexed citations

Hirano, Toshiyuki, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2018). Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 17(4). 740–750. 31 indexed citations

Hegab, Ahmed E., Mari Ozaki, Shizuko Kagawa, et al.. (2018). Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. Lung Cancer. 119. 25–35. 27 indexed citations

Nukaga, Shigenari, Hiroyuki Yasuda, Katsuya Tsuchihara, et al.. (2017). Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research. 77(8). 2078–2089. 131 indexed citations

10.

Miyawaki, Masayoshi, Hiroyuki Yasuda, Tetsuo Tani, et al.. (2016). Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. Molecular Cancer Research. 15(1). 106–114. 58 indexed citations

11.

Tani, Tetsuo, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2015). Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells. Molecular Cancer Therapeutics. 15(1). 162–171. 54 indexed citations

12.

Terai, Hideki, Kenzo Soejima, Hiroyuki Yasuda, et al.. (2013). Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC. Molecular Cancer Research. 11(7). 759–767. 174 indexed citations

13.

Patrick, C., Ramasamy Jagadeeswaran, Simha Jagadeesh, et al.. (2005). Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer. Cancer Research. 65(4). 1479–1488. 467 indexed citations

14.

Zhao, Xiaojun, Barbara A. Weir, Thomas LaFramboise, et al.. (2005). Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. Cancer Research. 65(13). 5561–5570. 242 indexed citations

15.

Paez, J. Guillermo, Pasi A. Jänne, Jeffrey C. Lee, et al.. (2004). EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science. 304(5676). 1497–1500. 7539 indexed citations breakdown →

16.

Ishii, Makoto, Yukio Suzuki, Kei Takeshita, et al.. (2004). Inhibition of c-Jun NH2-Terminal Kinase Activity Improves Ischemia/Reperfusion Injury in Rat Lungs. The Journal of Immunology. 172(4). 2569–2577. 55 indexed citations

17.

Sato, Nagato, Yukio Suzuki, Kazumi Nishio, et al.. (2000). Roles of ICAM-1 for Abnormal Leukocyte Recruitment in the Microcirculation of Bleomycin-induced Fibrotic Lung Injury. American Journal of Respiratory and Critical Care Medicine. 161(5). 1681–1688. 40 indexed citations

18.

Asano, Koichiro, et al.. (1999). Plasma Platelet-activating Factor Acetylhydrolase Deficiency in Japanese Patients with Asthma. American Journal of Respiratory and Critical Care Medicine. 159(3). 974–979. 30 indexed citations

19.

Suzuki, Koichi, Katsuhiko Naoki, Hiroyasu Kudo, et al.. (1998). Impaired Hypoxic Vasoconstriction in Intraacinar Microvasculature in Hyperoxia-exposed Rat Lungs. American Journal of Respiratory and Critical Care Medicine. 158(2). 602–609. 14 indexed citations

20.

Nishio, Kazumi, Yukio Suzuki, Takuya Aoki, et al.. (1998). Differential Contribution of Various Adhesion Molecules to Leukocyte Kinetics in Pulmonary Microvessels of Hyperoxia-exposed Rat Lungs. American Journal of Respiratory and Critical Care Medicine. 157(2). 599–609. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact